A new investigation found that such medicines can reduce the risk of Alzheimer's. While this new opportunity will take some time to cook before it's ready to delight shareholders, one of the two ...

Eiza Gonzalez and Will Poulter are the latest stars to join the cast of 'I Love Boosters'. The pair have signed up to appear in Boots Riley's movie where they will also be joined by Poppy Liu and ...

29 Oct - Veteran actress Lily Li was revealed to have recently passed away. The news was confirmed by veteran media personality Wang Man Ling, who shared a photo of the group of Shaw actresses that ...

Ian Brown writes immersive, deeply reported, narratively-driven feature stories about a wide variety of subjects. He began his professional life at The Financial Post, writing about real estate ...

EXCLUSIVE: Eiza González (Baby Driver), Poppy Liu (Hacks), Taylour Paige (Zola), and Will Poulter (The Bear) have closed deals to join I Love Boosters, Boots Riley’s next film for Neon ...

Bishop was removed from his position after he called popular golfer Ian Poulter a "lil girl." In an interview with Sports Illustrated's Bob Harig, Bishop opened up about that moment. He had posted ...

If Ted Bishop's story offers warning to high-ranking executives involved in sports, it's that social media can be a powerful tool in spreading views in an instant. The former president of the ...

Ian James is a reporter who focuses on water in California and the West. Before joining the Los Angeles Times in 2021, he was an environment reporter at the Arizona Republic and the Desert Sun.

READ MORE: The popular daily snack that could lower your risk of dementia Manufactured by Eli Lilly, donanemab is designed to slow down the progression of early Alzheimer's by targeting the causes of ...

A group of U.S. senators is digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this year in search of any indication the services could create conflicts of ...

Shares of Eli Lilly have gained considerably throughout 2024, thanks in large part to the company's success in diabetes and obesity care. Outside of weight loss, Eli Lilly has a major opportunity ...

It provided little detail other than saying that Eli Lilly had shown it could “meet the present and projected national demand,” while acknowledging that patients could still see periodic ...